Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Under 2 Years Old

• Status: Not yet recruiting
• Trial end date: 2026-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The object of the trial is to evaluate if point-of-care testing directed use of oral prednisolone is beneficial in acute wheezing induced by rhinovirus in children 6-24 months old.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oulu
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Wheezing diagnosed by a physician (expiratory obstruction)

• Requires salbutamol treatment at the emergency department

• Positive rhino- or picornavirus (POC-testing)

Exclusion Criteria:

• Need for immediate resuscitation

• Immediate transfer to ICU

• Suspicion of pneumonia based on the auscultation finding

• Suspicion of serious bacterial infection

• Another respiratory virus in the absence of rhino- or picornavirus

• Positive finding of RSV

• Positive finding of SARS-CoV-2

• Positive finding of M pneumoniae

• Positive finding of B pertussis

• Contact with a person suffering from chickenpox within 14 days

• Active chickenpox

• Suspicion of respiratory foreign body

• Immunosuppressive treatment

• Systemic cortisone treatment within 14 days

• Allergic of cortisone